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gp43 is the main diagnostic antigen for paracoccidioidomycosis (PCM). In vitro, gp43 expression in super-
natant fluids of Paracoccidioides brasiliensis cultures can be unstable, and its regulation is poorly understood.
We have been able to express soluble recombinant gp43 (gp43r) isoforms as N-mannosylated proteins secreted
in the supernatants of Pichia pastoris cultures induced with methanol. They were secreted as major components
from day 2 of induction and could be purified with affinity columns containing anti-gp43 monoclonal antibod-
ies. We have expressed P. brasiliensis GP43 (PbGP43) sequences from genotypes A, D, and E, and the
correspondent gp43r isoforms (gp43r A, -B, and -C, respectively; 200 ng) were compared to native gp43 in
immunodiffusion (ID) and dot blot assays. Among 90 PCM patient sera showing ID-positive reactions with
purified native gp43, 100% were positive with gp43rD and gp43rE and 98% reacted with gp43rA. Of these sera,
78 were tested in dot blot assays at a 1:1,000 dilution, and 100% reacted with all recombinant isoforms. In ID
assays, the specificity was 100%, since 40 sera from patients with related mycoses and 30 sera from healthy
individuals did not react with any of the antigens. In dot blot assays, 100% specificity for PCM occurred when
cross-reactive mannose epitopes were neutralized with 10 mM metaperiodate or eliminated through deglyco-
sylation. However, a 1:1,000 serum dilution was already discriminatory for most sera. We suggest that P.
pastoris recombinant gp43, especially isoforms D and E, may replace the native antigen in ID and dot blot
assays for diagnosis and prognosis of PCM. Regulated expression of large amounts of antigen in nonpatho-
genic yeast would justify its preferred use.
gp43 is a secreted glycoprotein from Paracoccidioides brasil-
iensis. It is the best-studied fungal molecule and the main
antigen for diagnosis and prognosis of paracoccidioidomycosis
(PCM) described so far (7, 20, 25, 37). PCM is a granuloma-
tous systemic mycosis that occurs as active disease in 1 to 2%
of infected people, whose number is estimated to be 10 million
throughout areas of endemicity in Latin America (32). Adult
PCM is the commonest form and gradually affects the lungs,
mainly of male adults; it can be unifocal or disseminate to any
organ, generally involving mucous membranes and skin. Acute
and subacute PCM progress rapidly and spread through the
lymphatic system; they are characteristic of children and young
adults of both sexes (14). Histoplasmosis, blastomycosis, and
coccidioidomycosis are related endemic mycoses caused by
dimorphic ascomycetes genetically close to P. brasiliensis (30).
Cellular immunity is protective against these mycoses, whereas
high antibody titers against fungal antigens suggest heavy fun-
gal loads during severe stages of disease.
Apart from being a major P. brasiliensis antigen for the
humoral response, gp43 also contains T-cell epitopes that elicit
protective cellular immunity in experimentally infected ani-
mals (17, 36, 37) and displays adhesive capacity toward pro-
teins associated with the extracellular matrix (15, 21). The
open reading frame of the P. brasiliensis GP43 (PbGP43) gene
lies within a 1,329-bp genomic fragment that has a single 78-bp
intron (11). The full protein bears 416 amino acids, of which
the first 35 correspond to a signal peptide. Mature or exocel-
lular gp43 contains a single N-glycosylation site at sequon
NRT, which is occupied by high-mannose chains composed, on
average, of 13 or 14 nonphosphorylated mannose residues and
one terminal -galactofuranose residue (-Galf) (3). The
-Galf residue is -1,6 linked to one of the -1,2-linked man-
opiranose residues added to the fixed Man7GlcNAc2 core. This
chain can be removed enzymatically with endoglycosidase H
(endo H) or N-glycosidase F, metabolically with tunicamycin,
and chemically with trifluoromethanosulfonic acid, generating
a faster-migrating single band in sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) gels (27). Exocel-
lular gp43 is composed of a mixture of isoforms that have close
but distinct isoelectric points (pI), as originally observed in P.
brasiliensis isolate Pb339 (25). Moura-Campos et al. (23) de-
scribed the existence of four gp43 pI profiles for eight fungal
isolates, suggesting that differences can occur both within and
among isolates. The antigen from one isolate was peculiarly
basic (8.5), while gp43 proteins from the others had pIs
varying from 5.8 to 7.2.
Morais et al. (22) found a total of 21 informative substi-
tution sites concentrated in exon 2 of the PbGP43 gene,
defining genotypes A to E (29). So far, all six samples bear-
ing genotype A have been grouped in a cryptic phylogenetic
group, PS2, according to a multilocus study with 65 isolates
conducted by Matute et al. (19). Genotype A sequences
translate basic gp43 and are highly polymorphic (up to 15
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substitution sites) compared with the others. Isolates from
PS2 were less virulent than others in the B10.A mouse
model of PCM (10).
Serological diagnosis and prognosis of PCM are important
tools for clinicians. The most popular test is double immuno-
diffusion (ID) for its simplicity, high sensitivity, and specificity
(9, 31). Whole P. brasiliensis extracellular antigen preparations
are commonly used, where gp43 is the antigenic component
responsible for ID specificity and positivity over 85% (5, 7, 9,
25). False-negative reactions have been found for patients with
intense pulmonary infection and immune depression (5, 9).
Purification of gp43 was facilitated after the production of
monoclonal antibodies (15, 27), and the antigen, purified or
not, has been tested in a variety of immunodiagnostic tests for
detection of patient antibodies (4, 8, 26, 35, 37). Antigen de-
tection in sera can also be used for diagnosis of PCM (18).
Although gp43 is quite specific for PCM when presented to
antibodies in solution (7, 26), in capture enzyme-linked immu-
nosorbent assays (ELISAs) (8), and in dot blot assays (35),
cross-reactions in ELISA can be frequent (1, 26), particularly
with -Galf residues, which are probably more exposed when
the antigen is immobilized on plastic.
Regulation of gp43 expression is poorly understood (10) and
varies with the isolate (34). However, instability in gp43 ex-
pression can occur even in good producers (e.g., strain Pb339).
Therefore, standardized whole-antigen preparations are useful
for diagnosis/prognosis (4, 7) but are not necessarily reproduc-
ible. On the other hand, differences in reactivity related to the
gp43 isoforms have already been reported (34). For these rea-
sons, the use of soluble recombinant gp43 (gp43r) would be a
step forward not only in the diagnosis of PCM but also in other
structural and biological studies.
In the present communication, we report the extracellular
expression of soluble gp43r in the yeast Pichia pastoris. Purified
gp43r was tested for reactivity with sera from patients with
PCM and other mycoses. We chose ID and dot blot assays to
compare the reactions with those of purified gp43 from Pb339
because they are simple and fairly specific tests according to
the literature (7, 35). Dot blotting is a sensitive enzymatic assay
(35) and can eventually be quantified (2). We managed to
express gp43 isoforms which are characteristic of Pb339 from
genotypes A, D, and E (gp43A, -B, and -C, respectively) but
not C (22, 29). The expressed isoform from genotype A has a
calculated pI of 8.3, while the translated sequences from ge-
notypes D and E have pIs of 6.8 and 7.1, respectively (22). Our
results suggest that gp43r produced in P. pastoris may be used
in the diagnosis of PCM, especially those isoforms from geno-
types D and E.
MATERIALS AND METHODS
Synthesis of PbGP43 cDNA and expression in P. pastoris. The PbGP43 coding
sequences corresponding to genotypes A, D, and E (29) were reverse transcribed
from DNA-free total RNA isolated from P. brasiliensis Pb3 (PbGP43 genotype
A), Pb10 (PbGP43 genotype D), and Pb14 (PbGP43 genotype E) (22). Total
RNA was extracted from logarithmically growing yeast cells cultivated at 36°C,
with shaking, in 0.5% yeast extract, 0.5% peptone-casein, and 1.5% glucose. The
cell pellet was mechanically disrupted by being vortexed with glass beads (425 to
600 m; Sigma) in the presence of TRIzol reagent (Invitrogen), and total RNA
was isolated according to the instructions of the manufacturer. cDNA of the
PbGP43 gene was obtained by reverse transcription-PCR (RT-PCR), using the
ThermoScript RT-PCR system (Gibco) and the specific 3 antisense primer 491
(5-ACGTCGACTCACCTGCATCCACCATACTT-3), which has a SalI site
immediately after the TGA stop codon. The second strand of the full open
reading frame was elongated, using standard PCR conditions, with the 5 sense
primer 490 (5-GTCAGATCTATCATGAATTTTAGTTCCTTAAC-3), con-
taining a BglII site before the ATG start codon, and with antisense primer 491.
The 490/491 PCR fragment (1,250 bp) was extracted from agarose gels by using
a Sephaglass kit (Amersham Pharmacia), cloned into the pGEM-T Easy vector
(Promega), and sequenced. cDNA corresponding to processed (secreted) gp43
was synthesized by PCR, using the pGEM-T clone as the template; the upstream
primer 690 (5-CAGTCGACAAGCAGGATCAGCAATATAT-3), containing
a SalI site before the alanine codon GCA; and the downstream primer 691
(5-GCGGTACCTCACCTGCATCCACCATA-3), where a KpnI site lies im-
mediately after the TGA stop codon. The 690/691 fragment (1,145 bp) was
purified, cloned into the pGEM-T Easy vector, and subcloned into the SalI/KpnI
sites of pHIS1 (33), which we previously used to express gp43(His6) in bacteria
(not published). Although the purified recombinant gp43(His6) isoforms ex-
pressed in bacteria have not been of further use because of solubilization prob-
lems, cloning into pHIS1 was essential for subcloning the 690/691 insert into the
EcoRI/NotI sites of a pPIC9 plasmid (Invitrogen) for expression in P. pastoris.
The correct frame at the 5 end was verified by sequencing recombinant pPIC9,
which was subsequently used to transform P. pastoris G115 according to the
manufacturer’s instructions.
A total of 10 recombinant clones from each PbGP43 genotype were ran-
domly selected for induction of gp43r expression with methanol. For that
purpose, individual colonies were grown for 2 days, with shaking, at 30°C in
BMGY (buffered minimal glycerol complex medium), composed of 1% yeast
extract, 2% peptone, 0.1 M potassium phosphate, pH 6.0, 1.34% YNB
(Difco), 1% ammonium sulfate, and 1% glycerol. Cell pellets were suspended
in one-half the initial volume of BMMY (BMGY with 1% methanol instead
of glycerol) and incubated at 30°C with intense shaking for 6 days. Methanol
(1%) was added daily, and aliquots of the culture were collected every 2 days
to monitor secretion of gp43r.
Screening of positive P. pastoris clones and purification of gp43r. We used dot
blotting to screen for P. pastoris gp43r-producing clones upon induction with
methanol. Cell-free supernatants (5 l) were dot blotted onto nitrocellulose
membranes and tested for reactivity with rabbit polyclonal anti-gp43 serum
(1:5,000), as described below. Purified native gp43 (gp43n) was used as a positive
control, and the supernatant from an induced P. pastoris culture expressing an
irrelevant protein was used as a negative control. Expression of gp43r by positive
clones was then verified in SDS-polyacrylamide-stained gels and Western blots.
We chose the best-producing clone of each isoform to induce larger cultures of
P. pastoris for 2 days for purification purposes. To purify gp43n and gp43r, we
used affinity columns of Affi-Gel 10 bound to MAb17c, which is an anti-gp43
monoclonal antibody that recognizes all gp43 isoforms (8; Rosana Puccia and
Ka´tia C. Carvalho, international patent application PCT/BR2007/000258, Fun-
dac¸a˜o de Amparo a` Pesquisa, 27 September 2007; Rosana Puccia and Ka´tia C.
Carvalho, Brazilian patent application priority PI 0604717-3, Brazilian Patent
Office, 29 September 2006).
ID assay. ID assays were performed on microscope slides covered with a layer
of 1% agarose gel diluted in 0.85% NaCl, as described previously (25). Antigens
(200 ng) and sera were tested in a volume of 10 l per well. Reactions were
incubated overnight at room temperature in a moist chamber; the slides were
then washed once in 5% sodium citrate and five times in 0.85% NaCl. The last
wash was extended overnight to minimize background staining. Agarose was
dehydrated over the slides in an oven, and the reactions were stained with
Coomassie brilliant blue.
Dot blotting. In order to test the usefulness of gp43r in dot blots, antigens (200
ng) were spotted onto nitrocellulose membranes (1.5 to 2 l), while for screening
purposes, 5 l of P. pastoris culture supernatant was used. The membranes were
left to dry in the air for 5 min and then quenched with sodium phosphate-
buffered saline (PBS) containing 5% skim milk (Nestle´) (PBS-M) overnight at
4°C. The membranes were washed three times (10 min each) with PBS-T (PBS
containing 0.1% Tween 20) and incubated with rabbit polyclonal anti-gp43 serum
(1:5,000) to screen for positive P. pastoris clones or with patient sera (1:300 or
1:1,000). Sera were diluted in PBS-M and incubated with shaking for 1 h at room
temperature with the membranes, which were then washed three times in PBS-T
and incubated with secondary antibodies (peroxidase-labeled goat anti-human
immunoglobulin G [IgG] or anti-rabbit immunoglobulin, used at 1:2,000; Amer-
sham Biosciences) for 1 h at room temperature, with shaking. The membranes
were washed three times, and the reactions were developed with diaminobenzi-
dine (Sigma). Preimmune serum or sera from healthy individuals were used as
negative controls.
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SDS-PAGE and Western blotting. Protein/glycoprotein profiles were visual-
ized upon silver impregnation and/or Coomassie brilliant blue staining after
electrophoresis in SDS-PAGE gels under reducing conditions (16). For Western
immunoblotting, the samples were transferred from SDS-PAGE gels to nitro-
cellulose membranes, and the reactions were performed with patient sera as
described previously (13). Immunocomplexes were evidenced with goat anti-
human IgG–peroxidase conjugates (Amersham Biosciences) and developed with
diaminobenzidine (Sigma).
Sera. Anti-gp43 rabbit immune serum and anti-gp43 monoclonal antibodies
were previously obtained by Puccia et al. (27, 28). Patient sera and sera from
healthy blood donors were obtained from Sa˜o Paulo Hospital. Some PCM
patient serum samples were kindly provided by M. H. S. L. Blotta, Unicamp,
Sa˜o Paulo, Brazil. We tested a total of 90 PCM serum samples from 78
diagnosed patients (with either the juvenile or adult form), most of whom
were undergoing treatment. Samples from the same PCM patients were
collected at different times of treatment. According to the records, original
ID titers for PCM patients were between 1:1 and 1:4, and a few were between
1:8 and 1:64 when sera were tested against whole exocellular P. brasiliensis
antigens from Pb339 (7).
Protein content. The gp43 protein content was estimated using (i) a modified
version of the Bradford methodology (6), (ii) optical density readings (1.0 A280
unit  0.45 mg/ml), and (iii) visualization in Coomassie brilliant blue-stained
SDS-PAGE gels.
RESULTS
We expressed three gp43 isoforms (gp43rA, gp43rD, and
gp43rE) as soluble glycoproteins in the culture supernatants of
selected recombinant P. pastoris clones. They were expressed
as major components migrating at about 45 kDa in SDS-PAGE
gels from the second day after induction with methanol (Fig.
1A). The peak of expression generally occurred between days
4 and 6 of culture. The major component was identified as
gp43r in Western blots incubated with polyclonal anti-gp43
rabbit antibodies (not shown).
The amount of gp43r expressed by P. pastoris varied with the
isoform. Upon induction of medium-scale yeast cultures with
methanol for 2 days, we obtained about 7 mg/liter of purified
gp43rD and gp43rE and over 100 mg/liter of purified gp43rA.
We chose to work with cultures induced for 2 days to minimize
the presence of P. pastoris molecules. However, in order to
increase the yield of gp43rD and -E, we might process longer-
induced cultures in future purifications. Purification was
achieved through affinity chromatography with columns con-
taining anti-gp43 monoclonal antibody (MAb17c), and the pu-
rified recombinant isoforms can be seen in Fig. 1B in compar-
ison with gp43n. In Fig. 1B, a smear is particularly visible for
gp43rD before treatment, suggesting hyper- and heteroge-
neous glycosylation by P. pastoris. The smear is more evident in
overloaded silver-stained gels (not shown) and can be seen in
the Western blot in Fig. 3C. After enzymatic deglycosylation
with endo H, all recombinant isoforms migrated slightly slower
than gp43n, probably due to the addition of 10 to 14 vector
amino acids at the N terminus. Although we have not se-
quenced this end of the gp43r isoforms, the constructions
predict the addition of a YVEFKGLRRQ peptide sequence
from pHIS1 and, possibly, the repeat EAEA from pPIC9
before that. This repeat is at the C terminus of the -mating-
factor signal peptide and is left in the recombinant proteins
produced in P. pastoris after Kex2 cleavage. Peptide EAEA
is supposedly cleaved by a dipeptidyl aminopeptidase, Ste13,
but cleavage may not occur when the protein is overex-
pressed (12).
We initially verified the reactivity of each gp43 isoform by
double ID assay, which is the test used most often for diagnosis
and prognosis of PCM because of its simplicity, sensitivity, and
specificity. We started by testing a small sample of PCM patient
sera that reacted with gp43n and obtained positive results using 2
g of all the isoforms. We next titrated the antigen (not shown) in
order to use the smallest possible amount to guarantee positive
results with pure sera. Based on the results, we chose 200 ng of
antigen to screen a larger serum sample. We assayed a total of 90
sera from 78 different patients (Table 1). The samples were tested
with gp43rA, gp43rD, and gp43rE in comparison with gp43n. In
Fig. 2A, we exemplify these reactions by showing the results for 18
PCM sera. The positive reactions between sera g, h, p, and o and
gp43rD were considered weak, while that between gp43rD and
serum n was negative (but positive in a second test). Among the
negative results, only two were later confirmed, specifically those
with isoform gp43rA (Table 1). However, these two sera pro-
duced weak reaction bands with the other antigens. The intensi-
ties of the precipitation lines were generally similar among iso-
forms and gp43n, but differences eventually occurred, as
represented by those formed between serum a or g and gp43rE.
In parallel, we tested sera from patients with histoplasmosis (n
15), aspergillosis (n  15), candidiasis (n  5), and Jorge Lobo’s
disease (n  5), in addition to 30 sera from healthy donors. The
antibodies in none of these sera produced ID precipitation bands
with gp43r or gp43n.
FIG. 1. (A) SDS-PAGE profiles of silver-stained total supernatant fluids from recombinant P. pastoris cultures (gp43rD) induced with methanol
for 2 to 6 days. gp43rD is indicated by an arrow. C, supernatant from P. pastoris, containing vector alone and induced for 2 days. (B) Purified gp43r
isoforms A, D, and E before () and after () treatment with endo H (EH). gp43n is shown for comparison. The gel was stained with Coomassie
brilliant blue stain. Molecular masses corresponding to standard protein bands are shown in kDa. The faster-migrating band seen in endo H-treated
gp43rD and gp43rE corresponds to the enzyme.
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In order to test the prognostic value of gp43r in ID assays, we
titrated (1:1 to 1:32) eight serum samples. As represented by
three sera in Fig. 2B, the results among gp43n and gp43r were
generally similar, although some differences in band intensity
could eventually be observed. Overall, our results showed that for
PCM diagnosis using ID, the positivity of gp43rD and gp43rE was
100% comparable to that of gp43n, while for gp43rA it reached
98% (Table 1). The specificity was 100% with all isoforms. We
concluded that gp43r produced in P. pastoris has ID diagnostic
and prognostic value for PCM. A mixture of isoforms is not
necessary, and isoform gp43rE apparently produced results most
similar to those obtained with gp43n.
We then tested the usefulness of gp43r in dot blotting. Among
ID-positive PCM patient serum samples, we assayed 78 with
gp43rA, gp43rD, gp43rE, and gp43n (200 ng), treated or not with
10 mM sodium periodate. A total of 33 sera were also tested with
the corresponding endo H-treated antigens. At a 1:1,000 serum
dilution, the reactions were generally similar among all antigens,
treated or not, as shown in the representative dot blots of Fig. 3A.
About 13 samples presented weaker dots, as exemplified by sera
PCM5 and PCM6. Reaction with PCM5 was the weakest among
PCM sera at 1:1,000. Sera from patients with other mycoses were
tested at 1:300, and at this dilution about 68% were positive with
all the gp43r isoforms, while 20% were positive with gp43n (Table
1). At 1:1,000, cross-reactivity with gp43n was abolished. Dilution
to 1:1,000 was also able to eliminate most of the cross-reactivity
with gp43r: among 13 positive sera at 1:300, only 3 had dots as
intense as or more intense than those for PCM5 (e.g., in Fig. 3B,
those for candidiasis and aspergillosis), while 6 dots were com-
pletely abolished and 4 were extremely weak (e.g., in Fig. 3B,
those for Jorge Lobo’s disease). False-positive reactions with sera
at a 1:300 or 1:1,000 dilution were totally abolished upon antigen
treatment with 10 mM metaperiodate (Fig. 3B), indicating that
they were due to cross-reactive carbohydrate epitopes. We also
assayed 30 sera from healthy individuals at 1:300, and 26 did not
react with any antigen tested, while in four cases there were
extremely weak dots visible with gp43r (similar to those in Fig. 3B
at 1:1,000 for Jorge Lobo’s disease), which disappeared after
metaperiodate treatment. The nature of the above-mentioned
cross-reactions is exploited in Fig. 3C. Control PCM patient se-
rum reacted intensely with gp43n and gp43r, and treatment with
metaperiodate did not qualitatively affect this reactivity. When
two histoplasmosis sera were tested under the same conditions,
there was no reactivity with treated antigens. Overmannosylation
is highly suggested by the smear seen for gp43rD. Our results
suggest that gp43r isoforms from P. pastoris are as successful as
gp43n in dot blot diagnosis of PCM; however, 100% specificity
can be achieved only upon neutralization of carbohydrate
epitopes with 10 mM metaperiodate or by deglycosylation, while
a test dilution at 1:1,000 eliminated most of the cross-reactions for
the samples tested here.
TABLE 1. Positive reactions between recombinant gp43r isoforms A, D, and E and serum samples from patients with PCM or other mycosesa
Sample group
% Positive reactions Total no. of








Per Per Per Per Per Per
PCM 98 100 100 100 100 100 100 100 100 90 78
Histoplasmosis 0 40 0 0 40 0 0 20 0 15 5
Aspergillosis 0 60 0 0 60 0 0 20 0 15 10
Candidiasis 0 60 0 0 80 0 0 0 0 5 5
Jorge Lobo’s disease 0 100 0 0 100 0 0 40 0 5 5
a Reactivity was tested in ID and dot blot assays. Dot blot reactions were performed before (Per) and after (Per) treatment with 10 mM sodium periodate. In
ID assays, all sera were tested undiluted, while in dot blots, PCM patient sera were tested at 1:1,000 and heterologous-protein sera were tested at 1:300. The percentage
of overall cross-reactivity highly decreased when heterologous sera were assayed in dot blots at 1:1,000 (not shown).
FIG. 2. Representative ID reactions with recombinant isoforms
gp43rA, gp43rD, and gp43rE and control gp43n (200 ng; central well).
(A) Undiluted PCM patient serum samples (a to s; 90 were tested)
reactive with gp43n. Overall results are shown in Table 1. (B) Titrated
PCM patient serum samples (from 1:1 [well 1] in twofold steps to a 1:32
dilution [well 6]). We show the reactions for PCM patient sera t, u, and v
(out of eight sera tested).
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DISCUSSION
We have been able to express soluble gp43r isoforms as
glycosylated proteins secreted in the supernatants of P. pastoris
cultures induced with methanol. The glycoproteins were se-
creted as major components from day 2 of induction and could
be purified in affinity columns containing anti-gp43 monoclo-
nal antibodies. We expressed PbGP43 sequences from geno-
types A, D, and E (29) and compared their performances with
that of gp43n in immunodiagnostic tests. The correspondent
gp43 isoforms were useful in both ID and dot blot assays to
detect 100% of PCM sera that were reactive with the native
antigen. With gp43r, we obtained total specificity for PCM
patient sera in ID assays, while in dot blots, total specificity for
PCM patient sera could be achieved when carbohydrate
FIG. 3. Representative dot blot reactions of PCM patient (1:1,000) (A) and heterologous-protein (1:300 or 1:1,000) (B) serum samples with
gp43n and gp43r isoforms A, D, and E (200 ng per dot) before (ct) and after (per) treatment with 10 mM metaperiodate. Some sera were also
tested against endo H-deglycosylated antigens (EH). (C) Immunoblotting profiles of gp43rD, treated (per) or not (ct) with 10 mM sodium
metaperiodate, as tested with a control PCM patient serum and two histoplasmosis antigen-reactive sera (Hc1 and Hc2), at a 1:1,000 dilution.
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epitopes were previously neutralized by treatment with 10 mM
metaperiodate or by enzymatic deglycosylation with endo H. In
most cases, however, a serum dilution of 1:1,000 was enough to
discriminate between PCM and heterologous sera.
We have previously made several efforts to express gp43r in
soluble form for use not only as an antigen in immunodiag-
nostic tests but also as a tool in diverse biological and structural
analyses. Our attempts included expression in both bacteria
and, unsuccessfully, Saccharomyces cerevisiae. For bacteria, we
reported the production of insoluble whole and truncated gp43
fused to glutathione S-transferase (13). In immunoblotting,
whole gp43–glutathione S-transferase reacted specifically with
27 PCM patient sera, while reactivity with N-terminal, middle,
and C-terminal fragments varied. Other vectors used for IPTG
(isopropyl--D-thiogalactopyranoside)-induced expression of
gp43 in bacteria included pET23-a (Novagen) and pHIS1 (33),
which resulted in production of insoluble His-tagged proteins
of limited antigenic capacity after solubilization with 8 M urea
and renaturation using standard protocols (not published).
For production of gp43 in P. pastoris, we subcloned PbGP43
genotypes A, D, and E from pHIS1 into both pPIC9K and
pPIC9 shuttle vectors, but we managed to express only the
gene cloned in pPIC9. We also tried to express gp43 isoform C
from Pb339, but so far this has been unsuccessful. Vectors
pPIC9 and pPIC9K differ basically in the resistance marker for
kanamycin, which is absent in pPIC9. The selection of trans-
formed bacteria relies on ampicillin resistance, and screening
for recombinant yeasts on histidine-deprived selection media
depends on vector-carried HIS4, coding for histidinol dehydro-
genase. The PbGP43 cDNA was cloned into pPIC9 between
the promoter and stop sequences from AOX1, which codes for
alternative oxidase, and in frame with the -factor leader se-
quence for secretion of large amounts of heterologous proteins
upon methanol induction. P. pastoris can use methanol as a
sole carbon source. We expressed gp43 in strain GS115 (his4)
transformed with recombinant pPIC9 restricted with SacI at
the 5 AOX1 promoter. Therefore, we obtained a His Mut
phenotype, where the plasmid is integrated in tandem into the
yeast genome upon homologous recombination at the pro-
moter site. In that situation, the AOX1 gene is not replaced,
hence preserving high methanol utilization (12). We have not
estimated the integration copy number for our recombinant
strains. Nevertheless, we obviously selected for the highest
gp43 producer of each isoform based on the intensities of the
reactions with anti-gp43 polyclonal rabbit serum during the
screening process of culture supernatants. Under our induc-
tion conditions, gp43rA was secreted about 15 times more
abundantly than gp43rD or gp43rE. This result suggests that
PbGP43(rA) was integrated into the P. pastoris genome at
higher copy numbers.
gp43r is glycosylated in P. pastoris. This yeast species is able
to add both N- and O-linked oligosaccharide chains to proteins
(12). The carbohydrate chains are constituted solely of man-
nose residues, and phosphorylation can occur in -1,2- or
-1,6-linked mannose residues. Differently from S. cerevisiae,
terminal -1,3-linked mannose is apparently not found in P.
pastoris due to a lack of the appropriate transferase. The oligo-
saccharide chains added to recombinant proteins in P. pastoris
are more commonly of the classical short high-mannose type
(Man8-14GlcNAc); however, there are examples of hyperglyco-
sylation (12). gp43r produced in this yeast migrates roughly at
a rate similar to that of gp43n in SDS-PAGE gels, but a
slower-migrating long smear can also be seen. This profile
suggests that the recombinant protein has the gp43 NRT se-
quon occupied mainly by short high-mannose chains, while
part has been overmannosylated with longer and heteroge-
neous chains, all of which are susceptible to endo H. The
presence of O-linked sugars or phosphorylated mannose resi-
dues has not been evidenced or investigated.
Differences in oligosaccharide composition or the presence
of vector amino acids in the N termini of gp43r isoforms did
not change their reactivity with PCM sera in ID assays com-
pared with gp43n reactivity. This was demonstrated by the
similar profiles generally seen in precipitation bands when sera
were tested either undiluted or titrated. On the other hand, ID
false-positive reactions were not observed either. Where false-
negative reactivity is concerned, isoform gp43rA, which is the
most polymorphic and renders basic gp43, was not recognized
by two sera reactive with gp43n and recombinant isoforms D
and E. Therefore, in future surveys, we will concentrate on the
use of isoform D or E. In a capture ELISA test using anti-gp43
MAb17c as the capture antibody, basic gp43 isoforms (geno-
type A) isolated from Pb1925 (Pb2) recognized fewer PCM
patient sera from both adult (71%) and juvenile (56%) pa-
tients than did purified gp43 from Pb339 (8). However, the
performances showed by both antigens were similar when
MAb8a was used. These data suggest that the epitope recog-
nized by MAb17c is shared by different gp43 isoforms and is
hence of special relevance in diagnosis.
It is noteworthy that in the present study we have not in-
cluded PCM sera that can be falsely negative in ID assays. We
worked exclusively with a random sample of PCM sera that
reacted with purified gp43 in this test. Neves et al. (24) inves-
tigated the nature of 28 proven PCM cases, all of the unifocal
pulmonary form, whose sera rendered false-negative ID results
with whole secreted antigens from Pb339. They demonstrated
by ELISA that in these patients the anti-gp43 antibodies were
preferentially of the IgG2a isotype, with low avidity for carbo-
hydrate epitopes. It is worth mentioning that in ELISA, gp43
carbohydrate epitopes are particularly accessible to antibody
recognition, prompting unwanted levels of cross-reactivity (1,
26) that are not characteristic of immunoprecipitation tests (7),
capture ELISA (8), or dot blots (35). PCM sera bearing anti-
bodies preferentially directed to gp43 carbohydrate epitopes
are exceptions and cannot guarantee serological diagnosis of
PCM. It would be interesting to test false-negative sera in dot
blot, quantitative dot blot (2), and ID assays with both native
and recombinant purified gp43 under conditions that could
favor recognition of peptide-specific epitopes, even at low
titers.
Although overmannosylation of gp43r did not interfere with
the specificity of ID results for PCM, the specificity of dot blot
reactions was compromised: false-positive reactions were de-
tected in dot blots performed at 1:300 and, at a smaller per-
centage, at a 1:1,000 serum dilution; however, the reactivity
was completely abolished when the antigens were previously
treated with metaperiodate or endo H. On the other hand,
PCM patient sera reacted equally well at 1:1,000 with gp43n
and gp43r. None became negative against treated antigens,
corroborating our previous observation that anti-gp43 antibod-
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ies from PCM patients are preferentially directed to peptide
epitopes (26). The rate of false-negative reactions with gp43n
in dot blots was 20% in this work and only 4.3% when Taborda
and Camargo (35) standardized the test for diagnosis and
prognosis of PCM. They tested 64 sera from non-PCM mycosis
patients and 50 sera from healthy individuals; treatment with
10 mM metaperiodate blocked cross-reactions. In the present
work, higher percentages of cross-reactivity with gp43r in dot
blots were expected due to the ubiquitous nature of mannose
epitopes among pathogenic fungi. In gp43n, the main source of
cross-reactivity seems to be a unique terminal -Galf residue,
at least when ELISA is considered (1, 26).
Overall, our results suggest that gp43r from P. pastoris may
replace gp43n in dot blots and ID assays for detection of PCM;
although a serum dilution of 1:1,000 eliminated most dot blot
cross-reactions, neutralization of carbohydrate epitopes is rec-
ommended to avoid false-positive results with this test. We
tested three isoforms, among which gp43rD or gp43rE can
apparently be used without the need for a mixture of isoforms.
The isoform corresponding to Pb339 (genotype C), which is
largely used for antigen production, has not been expressed
successfully in yeast so far. The advantage of gp43r from P.
pastoris relies mainly in reproducibility for the production of
large amounts of a known sequence of gp43, which is expressed
in culture supernatants under inducible conditions in non-
pathogenic, fast-growing yeast. Although posttranslational
modifications in yeast can be advantageous, we are working on
the expression of deglycosylated gp43r, using a point mutation
at the glycosylation site. That might render a more specific
antigen, but conformational problems could lead to decreased
sensitivity.
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